Allmed Medical(002950)2023-10-27 16:00Financial Performance - The company's revenue for Q3 2023 was ¥591,568,208.13, a decrease of 36.58% compared to the same period last year[5] - The net profit attributable to shareholders was -¥6,634,324.87, representing a decline of 92.88% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥42,631,405.57, down 18.55% from the previous year[5] - Total operating revenue for Q3 2023 was CNY 2,018,286,601.72, a decrease of 34.3% compared to CNY 3,067,161,380.95 in the same period last year[18] - Net profit for Q3 2023 was CNY 145,096,053.88, a decline of 26.3% compared to CNY 196,749,394.55 in Q3 2022[19] - The total comprehensive income for the third quarter was CNY 142,881,909.17, a decrease from CNY 289,534,919.49 in the previous period[20] Earnings and Shareholder Information - The company's basic and diluted earnings per share were both -¥0.0105, a decrease of 92.87% year-on-year[5] - Basic and diluted earnings per share for the quarter were CNY 0.2375, down from CNY 0.3109 year-over-year[20] - The total number of ordinary shareholders at the end of the reporting period was 45,447[11] - The top shareholder, Cui Jinhai, holds 23.02% of the shares, totaling 145,794,859 shares[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,176,168,600.57, a decrease of 9.94% from the end of the previous year[5] - The company's total assets as of September 30, 2023, amounted to CNY 5,176,168,600.57, a decrease from CNY 5,747,507,000.10 at the beginning of the year[16] - Current assets totaled CNY 1,828,283,232.00, down from CNY 2,398,959,626.70 at the start of the year, reflecting a decline of 23.8%[15] - The total liabilities decreased to CNY 1,940,298,066.35 from CNY 2,616,522,450.63, indicating a reduction of 26.0%[16] - The company reported a total equity attributable to shareholders of ¥3,211,265,730.42, an increase of 3.55% from the previous year[5] Cash Flow - The operating cash flow net amount for the year-to-date was ¥459,259,090.89, a decrease of 49.02%[5] - Net cash flow from operating activities was CNY 459,259,090.89, significantly lower than CNY 900,860,648.94 in the same period last year[22] - Cash inflow from operating activities totaled CNY 2,379,250,640.27, compared to CNY 3,691,129,338.86 in the previous year[21] - Cash outflow from operating activities was CNY 1,919,991,549.38, down from CNY 2,790,268,689.92 year-over-year[21] - Net cash flow from investing activities was negative CNY 147,989,850.38, an improvement from negative CNY 1,067,174,157.15 in the previous year[22] - Cash flow from financing activities resulted in a net outflow of CNY 422,568,982.11, compared to a net outflow of CNY 236,928,160.88 in the same period last year[22] - The ending balance of cash and cash equivalents was CNY 393,655,682.98, an increase from CNY 280,149,583.65 year-over-year[22] - The company's cash and cash equivalents increased to CNY 522,204,672.55 from CNY 393,948,041.15, representing a growth of 32.6%[14] Operational Costs and R&D - Total operating costs for Q3 2023 were CNY 1,807,626,230.75, down 32.4% from CNY 2,675,982,938.94 year-on-year[18] - The company reported R&D expenses of CNY 60,060,955.75 for Q3 2023, an increase of 31.5% compared to CNY 45,635,755.64 in the previous year[19] Inventory and Borrowings - Inventory as of September 30, 2023, was CNY 831,236,165.09, a decrease of 5.3% from CNY 877,326,555.66 at the beginning of the year[14] - Short-term borrowings decreased significantly to CNY 443,350,309.73 from CNY 792,092,140.47, a reduction of 44.1%[16] Audit Status - The company has not undergone an audit for the third quarter report[23]